Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season

scientific article

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.15585/MMWR.RR6602A1
P932PMC publication ID5837399
P698PubMed publication ID28841201

P50authorJoseph BreseeQ61189679
Daniel JerniganQ85342211
Alicia M FryQ87077992
P2093author name stringEmmanuel B Walter
Leslie Z Sokolow
Karen R Broder
Lisa A Grohskopf
P2860cites workIncidence of medically attended influenza during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance Project, 2009-13.Q30202827
Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United StatesQ30388312
High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 seasonQ30425045
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010Q34129986
Efficacy of high-dose versus standard-dose influenza vaccine in older adultsQ34433416
Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.Q36009663
Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adultsQ36154661
Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in PregnancyQ36201827
Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza VaccinationQ36306922
Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003-2004 and 2004-2005 influenza seasonsQ36964157
Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?Q37084793
Recommendations for the administration of influenza vaccine in children allergic to egg.Q37597769
Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011-12 through 2014-15.Q38403538
Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single seasonQ38420094
Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine.Q38438083
Influenza virus infection in travelers to tropical and subtropical countries.Q39284878
Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled TrialQ40073913
Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or OlderQ40151067
Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 monthsQ40318118
The underrecognized burden of influenza in young children.Q40475111
Prevention and Control of Seasonal Influenza with VaccinesQ40607746
Cruise ships: high-risk passengers and the global spread of new influenza virusesQ40615126
Febrile Seizure Risk After Vaccination in Children 6 to 23 MonthsQ40713270
Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 monthsQ40845505
Trials of Influenza A/New Jersey/76 Virus Vaccine in Normal Children: An Overview of Age-Related Antigenicity and ReactogenicityQ40879321
Clinical reactions and serologic response following inactivated monovalent influenza type B vaccine in young children and infantsQ40892205
Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first timeQ40931032
Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adultsQ40933588
Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccinesQ41089501
From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration. Summary of clinical trials of influenza vaccines--IQ41516459
Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailtyQ41574817
Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasonsQ42081471
Incidence and risk factors for acute respiratory illnesses and influenza virus infections in Australian travellers to AsiaQ42276385
Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistenceQ43174206
A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young childrenQ43174883
A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 yearsQ44955827
Reactogenicity and Immunogenicity of Bivalent Influenza Vaccine in One- and Two-Dose Trials in Children: A SummaryQ45056829
Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority studyQ47852548
Evaluation of the efficacy of split-product trivalent A(H1N1), A(H3N2), and B influenza vaccines: reactogenicity, immunogenicity and persistence of antibodies following two doses of vaccines.Q50576656
Large Summertime Influenza A Outbreak among Tourists in Alaska and the Yukon TerritoryQ51676032
Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12.Q54272482
Influenza- and RSV-associated hospitalizations among adultsQ57384999
Immunogenicity and Reactogenicity of 1 versus 2 Doses of Trivalent Inactivated Influenza Vaccine in Vaccine‐Naive 5–8‐Year‐Old ChildrenQ57385003
Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protectionQ57385728
Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in aQ57793454
Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control studyQ59617109
Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP)Q64131126
Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78Q69536044
Impact of epidemic type A influenza in a defined adult populationQ71461858
Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 seasonQ79396301
Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of ageQ80797079
Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and olderQ81379333
Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 dosesQ81920819
Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young childrenQ82214819
Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP)Q82636961
2013 IDSA clinical practice guideline for vaccination of the immunocompromised hostQ87092630
The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderlyQ87232318
P433issue2
P921main subjectimmunizationQ1415366
P304page(s)1-20
P577publication date2017-08-25
P1433published inMorbidity and Mortality Weekly Report: Recommendations and ReportsQ23930023
P1476titlePrevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season
P478volume66

Reverse relations

cites work (P2860)
Q47680688A multi-site feasibility study to assess fever and wheezing in children after influenza vaccines using text messaging.
Q92668947A paediatric influenza update 100 years after the Skyros island Spanish flu outbreak
Q64898397A population-based study of maternal and infant factors influencing influenza vaccination among young children born in Colorado from 2008 to 2016.
Q98186520A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season
Q92456759A review of the cost-effectiveness of adult influenza vaccination and other preventive services
Q91652613A study to evaluate the immunogenicity and shedding of live attenuated influenza vaccine strains in children 24-<48 months of age
Q88983080Actividades preventivas en la mujer. Actualización PAPPS 2018
Q50115044Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2018.
Q91614864Alternative-Dose versus Standard-Dose Trivalent Influenza Vaccines for Immunocompromised Patients: A Meta-Analysis of Randomised Control Trials
Q57469672An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States
Q63247049Announcement: National Birth Defects Prevention Month and Folic Acid Awareness Week - January 2018
Q59353186Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance
Q90209648Are children with special risk medical conditions receiving influenza vaccination? Validity of parental and provider report, and to a National Immunisation Register
Q64135849Association between patient reminders and influenza vaccination status among children
Q64137752Association between provider recommendation and influenza vaccination status among children
Q57178948Beliefs, attitudes, and barriers associated with the uptake of the seasonal influenza vaccine among patients visiting primary healthcare clinics
Q89965369Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics
Q64245361Burden, effectiveness and safety of influenza vaccines in elderly, paediatric and pregnant populations
Q61816519Can online self-reports assist in real-time identification of influenza vaccination uptake? A cross-sectional study of influenza vaccine-related tweets in the USA, 2013-2017
Q64054477Children under 10 years of age were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic in Canada: possible cohort effect following the 2009 influenza pandemic
Q91991655Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women
Q94672299Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season
Q91647242Compressed Influenza Vaccination in U.S. Older Adults: A Decision Analysis
Q92993339Cost effectiveness of school-located influenza vaccination programs for elementary and secondary school children
Q55716746Demographics, perceptions, and socioeconomic factors affecting influenza vaccination among adults in the United States.
Q92893309Determinants of Seasonal Influenza Vaccine Uptake Among the Elderly in the United States: A Systematic Review and Meta-Analysis
Q90314555Determinants of healthcare workers' willingness to recommend the seasonal influenza vaccine to diabetic patients: A cross-sectional survey in Ningbo, China
Q49926306Development and pilot testing of a text message vaccine reminder system for use during an influenza pandemic.
Q52589345Direct-to-adolescent text messaging for vaccine reminders: What will parents permit?
Q57814655Do parents prefer inactivated or live attenuated influenza vaccine for their children?
Q92499108Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis
Q64133134Effectiveness of trivalent inactivated influenza vaccine among community-dwelling older adults in Thailand: A two-year prospective cohort study
Q64130978Effects of Influenza Vaccination in the United States during the 2017-2018 Influenza Season
Q91238196Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles
Q92437525Evaluation of A(H1N1)pdm09 LAIV vaccine candidates stability and replication efficiency in primary human nasal epithelial cells
Q59351771Evaluation of the field-protective effectiveness of seasonal influenza vaccine among Korean children aged < 5 years during the 2014-2015 and 2015-2016 influenza seasons: a cohort study
Q89881323Factors associated with referring close contacts to an app with individually-tailored vaccine information
Q90344692Frequency and cost of live vaccines administered too soon after prior live vaccine in children aged 12 months through 6 years, 2014-2017
Q91774677Health outcomes of young children born to mothers who received 2009 pandemic H1N1 influenza vaccination during pregnancy: retrospective cohort study
Q89125909High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial
Q90419091Host Single Nucleotide Polymorphisms Modulating Influenza A Virus Disease in Humans
Q88310213How do we best prevent influenza in young children?
Q47169865Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization.
Q90597820Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study
Q43365954Impact of Human Immunodeficiency Virus on the Burden and Severity of Influenza Illness in Malawian Adults: A Prospective Cohort and Parallel Case-Control Study
Q50101280Impact of aging and HIV infection on serologic response to seasonal influenza vaccination
Q90128042Impact of funding influenza vaccination on coverage among Australian children: a national study using MedicineInsight, a large general practice database
Q91789123Improving Influenza Vaccination Coverage Among Patients With COPD: A Pilot Project
Q90858175Inactivated influenza vaccine effectiveness and an analysis of repeated vaccination for children during the 2016/17 season
Q64374818Incidence and seasonality of respiratory viruses causing acute respiratory infections in the Northern United Arab Emirates
Q90241630Infection prevention and chronic disease management in cystic fibrosis and noncystic fibrosis bronchiectasis
Q92763525Infections Caused by Influenza Viruses Among Children in Poland During the 2017/18 Epidemic Season
Q95363302Inflammatory Mediator Expression Associated With Antibody Response Induced by Live Attenuated vs Inactivated Influenza Virus Vaccine in Children
Q64123985Influenza
Q56985884Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance
Q47560061Influenza B virus infection and Stevens-Johnson syndrome.
Q58563490Influenza Vaccination in Older Adults: Recent Innovations and Practical Applications
Q91971734Influenza and Antibody-Dependent Cellular Cytotoxicity
Q58796174Influenza and Tdap Vaccination Coverage Among Pregnant Women - United States, April 2018
Q64135846Influenza vaccination among adults living with persons at high-risk for complications from influenza during early 2016–17 influenza season
Q93219467Influenza vaccination: Uptake and associations in a cross-sectional study of children with special risk medical conditions
Q90538926Influenza vaccine coverage, awareness, and beliefs regarding seasonal influenza vaccination among people aged 65 years and older in Central Saudi Arabia
Q64129863Influenza-Related Communication and Community Mitigation Strategies: Results From the 2015 Pandemic Influenza Readiness Assessment
Q49829189Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens
Q38957414Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017.
Q49981002Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018.
Q54232174Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8+ T cell responses.
Q87874410Intranasal influenza vaccine: Why does Canada have different recommendations from the USA on its use?
Q49974968Is Dr von Magnus to blame for the withdrawal of live attenuated influenza vaccine?
Q94423521Les recommandations relatives aux vaccins antigrippaux administrés aux enfants et aux adolescents pour la saison 2017-2018
Q93375313Licensing the first reduced, 6 µg dose whole virion, aluminum adjuvanted seasonal influenza vaccine - A randomized-controlled multicenter trial
Q64137087Low coverage rate and awareness of influenza vaccine among older people in Shanghai, China: A cross-sectional study
Q58122560Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice
Q92762684Modification of the vaccine manufacturing process improves the pyrogenicity profile of inactivated influenza vaccines in young children
Q60959439Modulation of Innate Immune Responses by the Influenza A NS1 and PA-X Proteins
Q64116962Novel Approaches for The Development of Live Attenuated Influenza Vaccines
Q52599675Novel Platforms for the Development of a Universal Influenza Vaccine.
Q92711478Oil-in-water emulsion adjuvants for pediatric influenza vaccines: a systematic review and meta-analysis
Q59349088Optimizing the impact of low-efficacy influenza vaccines
Q58584065Paid sick leave benefits, influenza vaccination, and taking sick days due to influenza-like illness among U.S. workers
Q41930762Perspectives from the society for pediatric research (SPR): Decreased effectiveness of the live attenuated influenza vaccine (LAIV).
Q92374807Prevalence and associated factors of influenza vaccination coverage in Korean adults with cardiovascular disease
Q92110843Prevalence of influenza and pneumococcal vaccine uptake in Saudi type 2 diabetic individuals
Q58709341Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season
Q64134459Prevention of influenza hospitalization among adults in the US, 2015-16: Results from the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)
Q53076429Preventive behaviors adults report using to avoid catching or spreading influenza, United States, 2015-16 influenza season.
Q90339280Prior vaccinations improve immunogenicity of inactivated influenza vaccine in young children aged 6 months to 3 years: A cohort study
Q87989165Probing Beyond Individual Factors to Understand Influenza and Pneumococcal Vaccine Uptake
Q92716364Racial disparities in U.S. maternal influenza vaccine uptake: Results from analysis of Pregnancy Risk Assessment Monitoring System (PRAMS) data, 2012-2015
Q57292231Racial/Ethnic Disparities in Influenza Vaccination Coverage Among US Adolescents, 2010-2016
Q57182362Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women
Q57093943Readiness for Responding to a Severe Pandemic 100 Years After 1918
Q101163380Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: Results of two revaccination studies
Q94587505Replication of live attenuated influenza vaccine viruses in human nasal epithelial cells is associated with H1N1 vaccine effectiveness
Q92760509SIMON, an Automated Machine Learning System, Reveals Immune Signatures of Influenza Vaccine Responses
Q58617792Safety and Immunogenicity of a Full-Dose Split-Virion Inactivated Quadrivalent Influenza Vaccine in Healthy Children 6 to 35 Months of Age: A Randomized Controlled Clinical Trial
Q57093614Seasonal Influenza Vaccine Impact on Pandemic H1N1 Vaccine Efficacy
Q64076721Seasonal influenza: Knowledge, attitude and vaccine uptake among adults with chronic conditions in Italy
Q93016369Should rare immunologic, neurologic, and other adverse events be indications to withhold vaccination?
Q57466491Temperature Sensitive Mutations in Influenza A Viral Ribonucleoprotein Complex Responsible for the Attenuation of the Live Attenuated Influenza Vaccine
Q89867698Tetanus, Diphtheria, and Acellular Pertussis and Influenza Vaccinations among Women With a Live Birth, Internet Panel Survey, 2017-2018
Q57166818The Future of Influenza Vaccines: A Historical and Clinical Perspective
Q46144181The challenge of vaccine policy-making with imperfect data.
Q90267717Transgender and Nontrans Patients Do Not Receive Statistically Different Quality Primary Care at Whitman-Walker Health, 2008-2016
Q58120075Understanding the unique characteristics of seasonal influenza illness to improve vaccine uptake in the US
Q54981943Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season.
Q41923696Update: Influenza Activity - United States and Worldwide, May 21-September 23, 2017.
Q47350852Update: Influenza Activity - United States, October 1-November 25, 2017.
Q92604918Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes
Q47595817Vaccination choices for older people, looking beyond age specific approaches
Q90036155Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient
Q50208587Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013-2014 season
Q89526678Vaccine hesitancy and influenza beliefs among parents of children requiring a second dose of influenza vaccine in a season: An American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) study
Q51409632Vaccine recommendations for children and youth for the 2017/2018 influenza season.
Q50056475Vaccine-associated hypersensitivity.
Q59352281Viral etiological causes of febrile seizures for respiratory pathogens (EFES Study)
Q91146451Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States
Q38690527Workplace interventions associated with influenza vaccination coverage among health care personnel in ambulatory care settings during the 2013-2014 and 2014-2015 influenza seasons
Q56765738Zoonotic Influenza and Human Health—Part 2: Clinical Features, Diagnosis, Treatment, and Prevention Strategies
Q59351197[Description of Influenza B in seasonal epidemics in Spain]
Q93344976[The universal influenza vaccination in children with Vaxigrip Tetra® in Italy: an evaluation of Health Technology Assessment]

Search more.